NCT00694083 2024-05-21
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
8 trialsNCT01380184 2019-04-19
MK-8669-059
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00110188 2015-11-20
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00060632 2015-08-27
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00060645 2015-08-27
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00288431 2015-07-22
Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00122343 2015-02-19
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00112372 2015-02-12
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed